Century Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Century Therapeutics, Inc. (IPSC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 488.76 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2023-03-16
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-12-31 was 54.75K shares, a 59.87% decline year-over-year.
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-09-30 was 136.43K shares, a 8.04% decline year-over-year.
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-06-30 was 136.42K shares.
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-03-31 was 161.16K shares.
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 488.76K shares, a 13.65% decline from fiscal 2021.
- Century Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 566.03K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2022-12-31 | 54.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 191.18K shares derived: sum of 2 quarters · filed 2023-03-16 | 327.60K shares derived: sum of 3 quarters · filed 2023-03-16 | 488.76K shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 136.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 272.85K shares derived: sum of 2 quarters · filed 2022-11-10 | 434.01K shares 10-Q · filed 2022-11-10 | 570.43K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 136.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 297.58K shares 10-Q · filed 2022-08-11 | 434.01K shares derived: sum of 3 quarters · filed 2022-08-11 | 582.35K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 161.16K shares 10-Q · filed 2022-05-16 | 297.58K shares derived: sum of 2 quarters · filed 2022-05-16 | 445.93K shares derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-12-31 | 136.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 284.77K shares derived: sum of 2 quarters · filed 2022-03-17 | 566.03K shares 10-K · filed 2022-03-17 | |
| 2021-09-30 | 148.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 429.61K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 281.26K shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |